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SUMMARY

Novel influenza A virus (IAV) strains elicit recall immune responses to conserved epitopes, making them
favorable antigenic choices for universal influenza virus vaccines. Evaluating these immunogens requires a
thorough understanding of the antigenic sites targeted by the polyclonal antibody (pAb) response, which single-particle electron microscopy (EM) can sensitively detect. In this study, we employ EM polyclonal epitope
mapping (EMPEM) to extensively characterize the pAb response to hemagglutinin (HA) after H5N1 immunization in humans. Cross-reactive pAbs originating from memory B cells immediately bound the stem of HA
and persisted for more than a year after vaccination. In contrast, de novo pAb responses to multiple sites on
the head of HA, targeting previously determined key neutralizing sites on H5 HA, expanded after the second
immunization and waned quickly. Thus, EMPEM provides a robust tool for comprehensively tracking the
specificity and durability of immune responses elicited by novel universal influenza vaccine candidates.

INTRODUCTION
Despite decades of endeavors to produce a lasting therapeutic
and effective vaccine, seasonal influenza virus still causes a
tremendous burden to public health each year, and pandemic
influenza virus is a constantly looming threat. To understand
the range of protection needed for seasonal and universal influenza virus vaccines (vaccines that can generate protection
against a broad array of influenza virus strains), we need a thorough characterization of humoral immune responses to influenza
virus vaccination (Erbelding et al., 2018).
Because of antigenic drift, that is, the ability of influenza virus
to mutate in response to selection pressures imposed by host
immune systems, seasonal influenza virus vaccines must be reformulated yearly and still result in only 10%–60% efficacy (Centers for Disease Control and Prevention, 2020). Current vaccines
are strain-specific, eliciting antibody responses primarily to the
variable head region of hemagglutinin (HA). This creates a challenge for generating vaccines to potentially pandemic strains,
since it is almost impossible to predict which strain can cause
a pandemic.
Highly pathogenic avian influenza (HPAI) H5N1 viruses have
been periodically crossing the species barrier from birds into humans, causing serious lower respiratory tract infections and viral
pneumonia (Claas et al., 1998; Peiris et al., 2007; Cowling et al.,

2013). H5N1 infections in humans result in up to 50%–60% mortality among clinically confirmed cases, in large part due to little
pre-existing immunity to avian influenza A virus (IAV) strains in
the human population (World Health Organization, 2020). However, due to frequent exposure to seasonal influenza virus HAs,
humans harbor memory B cells that are directed against epitopes shared between such HAs and H5 HA. These epitopes
predominantly reside within the conserved stem region of HA
and are the targets of broadly reactive antibodies (Throsby
et al., 2008; Ekiert et al., 2009). A major strategy for universal
influenza vaccine design is to re-focus immune responses to
the immuno-subdominant but conserved stem by immunizing
with HA from non-circulating influenza virus strains, such as
H5N1, thereby recalling matured memory B cells to sites shared
between influenza virus subtypes (Ellebedy et al., 2014; Nachbagauer et al., 2014; Nachbagauer and Palese, 2020). Rational vaccine design of subunit-based vaccines is well suited to this
endeavor, as this approach uses structural insight of epitopeparatope interactions to produce a vaccine that induces specific
and focused immune responses (Burton, 2010; Impagliazzo
et al., 2015; Yassine et al., 2015; Kanekiyo et al., 2019). To inform
rational vaccine design, there must first be a comprehensive
structural description of these conserved epitopes in complex
with antibodies, as well as an understanding of the dynamics
of the polyclonal antibody (pAb) response to these epitopes.
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Figure 1. Novel H5N1 vaccination elicits
robust IgG response to stem and head of
hemagglutinin (HA)
(A) H5N1 vaccine trial: 34 healthy adults received
the first immunization of inactivated H5N1
(A/Indonesia/5/2005) vaccine adjuvanted with
AS03 at day 0 and the second immunization at day
21. Blood samples were collected on days 0, 7, 21,
28, 42 or 100, and 500 after vaccination.
(B) ELISA binding titers of serum IgG to recombinant H5 HA during the course of vaccination.
(C) HAI titers of serum IgG to recombinant H5 HA at
days 0, 21, and 42 from subjects 4, 28, 36, and 43.
(D) ELISA binding titers of serum IgG to the head or
stem domains of H5 HA using H5 head-specific
(red) and stem-specific (blue) probes from subjects
4, 28, 36, and 43.
p values were determined by an unpaired t test:
*p < 0.05, **p < 0.01, ****p < 0.0001. N.S., not
significant. See also Figure S1.

Recent advances in evaluating antibody responses have produced a clearer picture of humoral immunity to IAV, yet such
techniques are still labor-intensive, time-consuming, and unable
to discern the full complexity of the pAb response (Wilson and
Andrews, 2012). For example, enzyme-linked immunosorbent
assays (ELISAs) reveal antibody reactivity to immunogens but
do not include information on targeted epitopes. Additionally,
isolation and characterization of monoclonal Abs (mAbs) represent a lengthy process involving multiple techniques and, due
to limited sampling ability, typically only represents a subset of
the pAb response. The application of single-particle electron microscopy (EM) to structurally characterize heterogeneous pAb
immune complexes from low to high resolution yields unprecedented insight into polyclonal immune responses following IAV
vaccination. We previously designed and implemented EM polyclonal epitope mapping (EMPEM) to discern the polyclonal immune response of rabbits and non-human primates to vaccination with HIV immunogens (Bianchi et al., 2018; Cirelli et al., 2019;
Moyer et al., 2020; Nogal et al., 2020). This structure-based strategy is highly efficient: sample preparation is straightforward, and
the pipeline from sample collection to structural results is
streamlined and expeditious, making longitudinal assessment
of polyclonal responses in multiple subjects over a vaccination
trial feasible.
In a previous study that characterized B cell responses of
H5N1 (A/Indonesia/5/2005) vaccinated subjects, Ellebedy et al.
(2020) demonstrated robust HA-specific plasmablast responses
in trial participants following H5N1 vaccination with AS03 adjuvant. In these subjects, the first dose of H5N1 vaccination elicited cross-reactive, stem-specific memory B cells and highly
mutated antibodies with some microneutralization activity while
the second dose elicited head-specific, naive B cells and minimally mutated antibodies with receptor binding site (RBS)
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neutralization activity (Ellebedy et al.,
2020). In the present study, we dive
deeper into the same patients and use
EMPEM to map the landscape of human
pAbs to HA at several time points after two doses of H5N1 vaccination from day 0 through 500. We detect persistent pAb responses to conserved epitopes on the stem domain of HA as
well as pAb responses to the vulnerable sites on the head
domain of HA that are also targeted during natural H5N1 infection in humans (Zuo et al., 2015). By charting the diverse
and complex pAb responses to H5N1 vaccination through
500 days our study provides epitope-level insight to inform immune-focusing, rational vaccine design strategies.
RESULTS
Robust serum response to H5N1 vaccination
To assess the humoral response to vaccination with a novel
strain of influenza, we obtained serum from human subjects
who participated in a pandemic H5N1 vaccination trial (ClinicalTrials.gov: NCT01910519, A/Indonesia/5/2005 H5N1) (Ellebedy
et al., 2020). The monovalent vaccine with Adjuvant
System 03 (AS03), a squalene-in-water emulsion adjuvant,
was administered in two immunizations at day 0 and day 21
(Figure 1A). Sera were collected at days 0, 7, 21, 28, 42, 100,
and 500 to measure the humoral response to H5N1 vaccination
(Figure 1A).
In our previous work, through analysis of isolated mAbs we
distinguished naive and memory B cell dynamics of subjects 4,
28, 36, and 43 (Ellebedy et al., 2020). In the present study, we
structurally characterized serum from these four subjects, with
serological analyses to contextualize structural assessments.
We observed an increase in H5-HA-specific serum immunoglobulin G (IgG) titers throughout the trial, with peak levels around
42 days after the first vaccination (Figures 1B and S1A). HAI titers, a measurement of the ability of HA to crosslink red blood
cells through binding its receptor, sialic acid, increased after
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To dissect head- and stem-targeting pAbs in serum, we performed ELISAs using probes of the trimeric HA head domain
alone and a chimeric construct containing H5 stem and H9
head, as described previously (Ellebedy et al., 2020). Immediately following the first immunization, stem-specific serum IgG
levels increased and remained high through 100 days after
vaccination (Figure 1D). Conversely, head-specific serum IgG
levels remained around baseline after the first immunization
but rose drastically after the second immunization and remained
elevated through 100 days after vaccination (Figure 1D). Monoclonal antibodies isolated from plasmablasts at days 7 and 28
from subjects 4, 28, 36, and 43 supported the head- and stemspecific dichotomy: day 7 mAbs targeted the stem while day
28 mAbs targeted the head of HA (Ellebedy et al., 2020). Affinity-matured B cells produce antibodies with high somatic hypermutation (SHM) and strong affinity, while naive or new memory B
cells produce antibodies with minimal mutations and low affinity
(Kurosaki et al., 2015). We observed that day 7 mAbs had higher
SHM loads (determined previously: Ellebedy et al., 2020), stronger affinities, and slower off-rates than did day 28 mAbs (Figures
S1B-S1E). These data suggest that affinity-matured memory B
cells targeting the stem of HA responded quickly to novel
H5N1 antigen but naive or minimally mutated memory B cells responded to the head of HA only after a second exposure to H5N1
antigen (Ellebedy et al., 2020).
While traditional serological analyses generate useful information about binding and functionality of pAb responses as a
whole, they do not reveal details about epitopes and binding
specificities of individual pAbs. Thus, we used EMPEM to chart
the epitope landscape targeted by pAbs over time.

Figure 2. EM polyclonal epitope mapping (EMPEM) generates
epitope landscapes from single particles
(A) Overview of EMPEM technique. In the vaccine regimen stage human
subjects are immunized (1) and serum samples are collected throughout the
course of the trial (2). During the antibody purification stage, IgG is extracted
from serum samples (3) and digested with papain to Fab (4). Resulting Fabs are
complexed with antigen (5). In the EM epitope imaging stage, immune complexes are imaged by EM (6), single-particle EM data are analyzed (7), and
epitope landscapes are assembled.
(B) Overview of EM data processing steps. Single-particle EM data are
collected, and particles are categorized into 2D class averages. Scale bar
represents 200 nm. 2D classes of immune complexes are further categorized
by another round of 2D classification and subjected to 3D classification and
refinement. Finally, polyclonal complex assemblies are generated by segmenting and resampling densities corresponding to each Fab and mapped
onto an HA trimer.
See also Figure S2.

the second immunization in the four donors, suggesting that
serum IgG at later time points can neutralize by blocking HA receptor binding activity (Figure 1C).

pAbs elicited by H5N1 vaccination bind the stem, head,
and vestigial esterase domains of HA
EMPEM is a visual proteomics method that encompasses
vaccination sample collection, antibody isolation and immune
complex purification, and single-particle EM image analysis (Figure 2). Following vaccination and antibody purification, we complexed HA with a large molar excess of Fab and purified immune
complexes by size exclusion chromatography, where a protein
peak corresponding to the immune complex and unbound
trimer separated from the excess Fab peak (Figures 2A and
S2). During EM imaging and data processing, we collected micrographs, extracted single particles, and categorized particles
by similarity through multiple rounds of 2D classification (Figure 2B). In the 2D class averages, we can already detect
numerous pAb specificities and assign targeted epitopes.
Next, we performed multiple iterations of 3D classification and
refinement of immune complexes. Finally, we represented 3D reconstructions of each pAb specificity on one protomer of the HA
trimer to generate epitope landscapes of each subject and time
point (Figure 2B).
To characterize the dynamics of the pAb response to H5N1
vaccination, we performed EMPEM on serum samples from
four subjects. For the first subject (subject 4), we processed
sera from days 0, 7, 21, 28, 42, and 500 and complexed pAbs
with the vaccine strain-matched HA (A/Indonesia/5/2005, Figures 3 and S3). At day 0, we did not observe any HA-specific
pAbs in 2D class averages (Figure 3A). By day 7 and day 21,
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Figure 3. Kinetics of the polyclonal antibody
(pAb) response to H5N1 vaccination in
subject 4
Negative stain EM reconstructions of subject
4 pAbs in complex with recombinant H5 HA
(A/Indonesia/5/2005) at days 0 (A), 7 (B), 21 (C), 28
(D), 42 (E), and 500 (F) after vaccination. Top left
panel: representative 2D class average. Bottom left
panel: 2D class average with the Fab labeled. Right
panel: side view of polyclonal immune complexes.
Stem specificity, blue; RBS-proximal and lateral
patch specificities, red, orange, and yellow; vestigial esterase specificity, pink. Due to limited particle representation, Fab graphics with dashed outlines are predicted placements. See also Figure S3.

we observed stem-specific pAbs binding H5 HA (Figures 3B and
3C). These stem-specific pAbs are likely cross-reactive recalled
antibodies elicited to conserved epitopes in the HA stem domain
by prior seasonal influenza infection or vaccination, as day 7
mAbs were affinity matured and exhibited high SHM (Figure S1;
Ellebedy et al., 2020). By day 28, 1 week after the second immunization, we observed pAbs still targeting the stem domain of HA
as well as pAbs targeting the head domain at multiple angles and
orientations around the RBS, lateral patch, and vestigial esterase
domain (Figure 3D). By day 42, pAb responses to the RBS, vestigial esterase domain, and stem domain persisted while other
head-targeting pAbs waned (Figure 3E). Finally, after day 500,
stem-specific pAbs remained circulating in low abundance (Figure 3F). Overall, subject 4 recalled cross-reactive stem-specific
pAbs immediately following H5N1 vaccination that persisted
more than 1 year after vaccination and also elicited a transient
wave of pAbs targeting the head and vestigial esterase domains
after the second immunization.
We extended EMPEM analyses to three more subjects in the
H5N1 vaccination trial (Figures 4 and S4). At day 0, two of the
subjects (36 and 43) already showed a stem-specific pAb
response to H5 HA. These pAbs must therefore have been circulating in serum before H5N1 vaccination and cross-reacted with
the vaccine antigen. By day 7, all subjects recalled a strong
stem-specific memory pAb response to H5 HA (Figure 4A).
These are likely broadly cross-reactive pAbs elicited by previous
seasonal vaccination or infection. At day 21, the day of the second immunization, subject 43 had already elicited a pAb
response to the RBS of H5 HA (Figure 4A). By day 28, all subjects
maintained stem-specific pAb responses (Figure 4A) while elicit-
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ing head-specific pAb responses to varying degrees. Subjects 4 and 43 exhibited
pAb responses to the RBS, lateral patch,
and vestigial esterase domain. Subjects
28 and 36 had a less diverse head-specific response to the RBS or to the midlateral region of the head. At intermediate
time points (day 42 for subject 4 and day
100 for subject 43; serum was unavailable
for subjects 28 and 36 at these time
points), pAbs targeting the RBS, vestigial
esterase, and stem domains remained in
circulation (Figure 4A). Expansion of pAbs against epitopes on
the head of HA was consistent with the increase in HAI titers after
the second immunization (Figures 1C and 4). After 500 days all
subjects with serum available demonstrated a lasting stem-specific pAb response (Figure 4), and subject 28 also displayed an
RBS-specific pAb response.
In summary, the landscape of pAbs responding to H5N1
vaccination followed two concurrent trends: stem-specific
pAbs targeted H5 HA from baseline through 500 days (Figure 4B).
These pAbs may have been circulating in serum before vaccination, recalled shortly after the first immunization, or newly elicited
after the second immunization. Head-specific pAbs expanded
after the second immunization, targeting the RBS, lateral patch,
mid-lateral head region, and vestigial esterase region, and they
waned quickly as the trial progressed, with the pAbs targeting
more conserved regions enduring longer (Figure 4B). Taken
together, these data demonstrate that H5N1 vaccination elicits
a prominent and prolonged pAb response to the conserved
stem domain of HA, as well as a more diverse and transient
pAb response to the variable, immunodominant head domain
of HA.
The kinetics of the polyclonal response mapped by EM are
consistent with serum ELISA and HAI data showing that stemspecific antibodies were already present at day 0 and continually
increased during the course of vaccination, while head-specific
antibodies and HAI+ antibodies were substantially present only
after the second immunization (Figures 1C, 1D, and 4). By day
42 or 100, serum IgG binding titers were still high for the majority
of subjects but were declining for donors 4 and 43 (Figures 1B
and 1D). In agreement, the EM-mapped pAb landscape at these
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Figure 4. Polyclonal antibodies elicited by
H5N1 vaccination decorate the stem, head,
and vestigial esterase domains of HA
(A) Matrix of negative stain EM reconstructions
of pAbs in complex with recombinant H5 HA
(A/Indonesia/5/2005) from each subject at all time
points listed. 3D reconstructions of polyclonal
immune complexes are shown for most time
points. Due to limited particle representation, Fab
graphics with dashed outlines are predicted
placements. For samples with immune complexes
in low abundance, example 2D class averages with
labels are shown.
(B) Summary of epitopes targeted by pAbs. Each
square represents a Fab specificity from the corresponding subject and time point. Stem specificities, blue and green; RBS-proximal and lateral
patch specificities, red, orange, and yellow; vestigial esterase and mid-lateral head specificities,
light pink and dark pink.
See also Figure S4.

intermediate time points was less diverse for donors 4 and 43.
Perhaps more dominant pAbs persist at high levels through
these time points while the more transient pAbs wane.
H5N1 vaccine-elicited mAbs target discrete regions on
HA and share footprints with pAbs
Previously, Ellebedy et al. (2020) characterized a panel of mAbs
isolated from these subjects and identified a biphasic response:
day 7 mAbs exclusively targeted the stem of HA with high SHM
and breadth, while day 28 mAbs targeted the head of HA with little
SHM and strain- or subtype-specific reactivity. In this study, we
complexed mAbs at days 7 and 28 from subjects 4 and 43 with
H5 HA (A/Indonesia/5/2005) to compare the binding footprints
and orientations with pAbs at day 28. All day 7 mAbs used the
heavy chain variable region VH1-69 germline and targeted the
same footprint on the stem of HA (Figures 5A, S5A, and S5B). While
day 28 mAbs utilized a mixture of germlines, including three mAbs
with VH3-33, six of the seven mAbs targeted the same footprint on
the RBS of HA (Figures 5C, S5A, and S5C). The seventh mAb targeted the vestigial esterase domain of HA (Figure 5B). Upon
comparing the footprints of these mAbs with day 28 pAbs from
subjects 4 and 43, we observed that each day 7 mAbs overlapped
almost perfectly with the blue stem-specific pAbs (Figure 5D).
Additionally, each day 28 RBS-specific mAbs overlapped almost

exclusively with each other and were represented by pAbs (Figure 5D). Finally, while
we were unable to obtain a 3D reconstruction of day 28 1B02 mAbs, 2D class averages confirmed that they bound the vestigial esterase domain in the same vicinity
as the vestigial esterase-specific pAbs
(Figures 5B and 5D).
To compare the cross-reactive potential
of mAbs from days 7 and 28, we complexed each mAb with HAs from heterosubtypic strains, including H1N1 (A/California/04/2009), H2N2 (A/Singapore/1/
1957), and H3N2 (A/Singapore/INFIMH-16-0019/2016; Figure 5E).
As expected, day 7 stem-specific mAbs demonstrated broad
cross-reactivity, binding H5, H1, and H2 HAs, while day 28
head-specific mAbs demonstrated subtype- or strain-specific
reactivity, binding only H5 HA.
Out of six pAb footprints identified by EMPEM only three were
represented by mAbs, suggesting that mAb analysis did not fully
recapitulate the diversity of the polyclonal response. Additionally, while day 28 mAbs targeted the head of HA almost exclusively (Figures 5C and 5D), ELISA data of serum IgG also demonstrated binding activity to the stem of HA at day 28 (Figure 1D),
further highlighting the role of pAb mapping to elucidate the
complete polyclonal response at the serum level. However,
mAb data provide valuable functional information and are complementary with EMPEM data; taken together, these results suggest that pAbs at day 7 are dominated by robust and broadly
cross-reactive VH1-69 stem responses while pAbs at day 28
target variable head epitopes and continue to target broadly
cross-reactive stem epitopes.
Cross-reactive immunity by H5N1 vaccine-elicited pAbs
After characterizing polyclonal epitope landscapes at low resolution, we next aimed to decipher molecular details of epitope-paratope interactions through cryoEMPEM on polyclonal sera. As
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Figure 5. H5N1 vaccine-elicited mAbs
target discrete regions on HA and share
footprints with pAbs
(A–C) Side views of negative stain EM reconstructions or 2D class averages show that
subjects 4 and 43 day 7 mAbs target the stem
domain (A) while day 28 mAbs target the vestigial
esterase domain (B) and the RBS (C) of recombinant H5 HA (A/Indonesia/5/2005).
(D) Comparison of subjects 4 and 43 mAb and pAb
immune complexes. Due to limited particle representation, orange, yellow, and pink pAbs from
subject 43 are predicted placements.
(E) Cross-reactivity of example mAbs from subjects 4 and 43 to recombinant HAs from A/
Indonesia/5/2005 (H5N1), A/California/04/2009
(H1N1), A/Singapore/1/1957 (H2N2), and A/
Singapore/INFIMH-16-0019/2016 (H3N2). mAbs
are shown in solid colors: 4.7.1C01, pale blue;
43.7.1A06, light blue; 43.7.1B02, teal; 43.7.1B04,
dark blue; 4.28.1F03, purple; 4.28.1H09,
lavender; 43.28.1A02, plum; 43.28.1A08, maroon;
43.28.1H01, brick; and 43.28.1E01, brown. pAbs
from day 28 are shown in colored mesh: stem
specificities, blue and green; RBS-proximal and
lateral patch specificities, red, orange, and yellow;
vestigial esterase and mid-lateral head specificities, pink.
See also Figure S5.

serum samples were already depleted from our previous study
as well as negative stain EMPEM, we only had enough serum
to perform this analysis on pAbs from subject 4 at day 28. We
processed cryoEM data using a focused classification data analysis pipeline (Figure S6A) (Zivanov et al., 2018) that enabled
detection and reconstruction of minority immune complexes
from total particles.
We discerned high-resolution immune complexes of pAbs
from subject 4 at day 28 that targeted the stem and multiple sites
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on the head of HA from a single cryoEM
sample (Figures 6A, 6B, and S6B–S6E).
Importantly, these epitopes corroborated
the negative stain epitope landscape for
subject 4 at day 28, demonstrating that
the lower resolution negative stain methodology was sufficient to observe all
epitopes. Due to limited serum sample
availability each immune complex in our
cryoEM images was present in low abundance—the stem specificity accounted
for 4% while each of the three head
specificities represented just 1%–2%
of the total particles. Nevertheless,
focused classification enabled us to
detect and reconstruct these antibodyepitope interactions. The RBS-binding
pAb plugged the receptor binding pocket
on HA, likely blocking receptor binding
(red epitope, Figures 6A, 6B, and S6B).
The remaining head-binding pAbs targeted the lateral patch (yellow) and vestigial esterase (pink) epitopes (Figures 6A, 6B, and S6B).
Intriguingly, the stem-specific pAb (Figures 6A–6C) bound in
almost the exact same location and orientation as CR9114, a
VH1-69 prototypical stem-directed broadly neutralizing Ab (Figure S6F) (Dreyfus et al., 2012; Lee and Wilson, 2015). The VH169 lineage broadly reactive mAb 1C01 from subject 4 superimposed almost perfectly with the stem-binding pAb, suggesting
that this mAb is part of the polyclonal response at that specificity
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Figure 6. High-resolution cryoEM defines
broadly reactive epitopes of H5N1 vaccineelicited pAbs
(A) CryoEM-mapped epitopes targeted by pAbs
from subject 4 at day 28. RBS epitope, red; lateral
patch epitope, yellow; vestigial esterase epitope,
pink; VH1-69 epitope, blue.
(B) Each epitope specificity marked together on a
single trimer.
(C and D) CryoEM map of stem immune complex
from subject 4 at day 28 with ribbon diagrams for
H5 HA (A/Indonesia/5/2005, gray; PDB: 4K62) and
mAb 1C01 from subject 4 day 7 docked into the
EM density. Full-length side view (C) and zoomed
in view of the epitope-paratope interaction (D). VH,
blue; VL, green; CDRH2, dark blue; CDRH3, purple;
HA residues H18 and W21, red.
See also Figure S6.

(Figures 5A and S6G). Upon docking the predicted structure of
the variable regions of 1C01 mAb into the cryoEM pAb density,
we observed that the pAb interaction appears to be mediated
by the signature IFY motif in CDR H2 and H3 that likely interacts
with H18 in HA1 and W21 in HA2 (Figures 6C–6D) (Dreyfus et al.,
2012; Lee and Wilson, 2015). Thus, high-resolution cryoEM mapping identified a broadly neutralizing CR9114-like stem response
in polyclonal sera following H5N1 vaccination, supporting components of the novel H5 antigen as a prime candidate for a universal influenza vaccine.
The major vulnerable sites (VSs) on the head of H5 HA have
been determined previously based on protective neutralizing
mAbs isolated from humans who recovered from HPAI H5N1 infections (VS1–VS3) and mice immunized with HPAI H5N1 (VS4)
(Zhu et al., 2013; Zuo et al., 2015). We mapped these vulnerable
sites onto the H5 HA trimer and compared them to negative stain
EMPEM epitopes (Figure 7A). The footprints of H5N1 vaccineelicited pAbs determined by both negative stain and cryoEM encompassed each of the vulnerable sites, including the RBS in
VS2 (red), lateral patch in VS1 (yellow), and vestigial esterase
domain bridging VS3 and VS4 (pink; Figures 6A, 6B, and 7A).
The major vulnerable sites were determined based on protective
neutralization activity. Although antibody responses to the stem

can have neutralizing activity, they can
also protect through effector functions
such as antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis (DiLillo et al.,
2014; Cox et al., 2016; Coughlan and Palese, 2018; Boudreau and Alter, 2019).
H5N1 vaccine-elicited pAbs also targeted
the stem domain, but they were not
represented in the characterization of
neutralizing responses to H5N1 infection
(Zuo et al., 2015). In summary, H5N1
vaccine-elicited head pAb responses
mimic homosubtypic broadly neutralizing
mAb responses to natural HPAI H5N1
infection.
To investigate the heterosubtypic breadth of polyclonal antibodies elicited by H5N1 vaccination, we examined the ability
of pAbs from donor 43 at day 21 to bind H1 HA using EMPEM
(Figures 7B and S7). We assessed cross-reactivity to the antigenically drifted A/Michigan/45/2015 (H1N1) HA that emerged
in 2015. As serum samples were isolated from subjects in
2013, the subjects were naive to this H1N1 strain. Due to limited
serum sample availability, we were only able to perform this analysis on one time point. However, we saw pAbs targeting the
broadly cross-reactive VH1-69 epitope on the stem of H1 HA,
suggesting that H5N1 vaccination elicits pAbs that recognize
multiple influenza virus subtypes. Moreover, these results
demonstrate that EMPEM can sensitively detect pAb responses
to strains of different subtypes than the vaccine strain.
To compare the epitope landscapes after H5N1 vaccination
with known broadly neutralizing responses, we superimposed
H5N1-reactive broadly neutralizing antibodies (bnAbs) with
pAbs from subject 4 at day 28 (Figure 7C) (Sun et al., 2014;
Lee and Wilson, 2015). As described above, the bnAb CR9114
that protects against both influenza A and B viruses mapped
almost exactly with vaccine-elicited stem pAbs and VH1-69
mAbs (Figures S6F, S6G, and 7C) (Dreyfus et al., 2012). Similarly,
bnAbs toward the vestigial esterase (H5M9, pan-H5N1 reactive)
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Figure 7. H5N1 vaccine-elicited pAb response mimics natural
infection and generates heterosubtypic immunity
(A) H5 HA (A/Indonesia/5/2005) with vulnerable sites (VSs) marked in yellow for
VS1, red for VS2, dark pink for VS3, and light pink for VS4. Footprints of pAbs
from all subjects at day 28 are outlined in black.
(B) Negative stain EM reconstruction of subject 43 pAbs in complex with recombinant H1 HA (A/Michigan/45/2015) at day 21. Stem specificity, blue.
(C) Subject 4, day 28 negative stain epitope landscape with broadly neutralizing antibodies docked into HA density. bnAb S139/1 (PDB 4GMS), orange;
bnAb H5M9 (4MHH), pink; bnAbCR9114 (4FQI), blue.
See also Figure S7.

and RBS (S139/1, group 1 and 2 cross-reactivity against H1, H2,
H3, H5, H9, and H13) also overlapped footprints and angles of
approach with pAbs (Figure 7C) (Yoshida et al., 2009; Lee
et al., 2012; Zhu et al., 2013). These results suggest that H5N1
vaccination elicits pAb responses to regions of broadly neutralizing epitopes.
DISCUSSION
Comprehensive mapping of the HA epitopes targeted by the pAb
response remains a major gap in our understanding of the human
B cell response to influenza viruses. EMPEM is a unique modality
that sensitively detects minority antigen-specific antibodies,
providing a comprehensive landscape of the polyclonal immune
response. In this study, we show that EMPEM can directly inform
rational design of a universal influenza vaccine by extensive
characterization of pAb responses to a vaccine derived from
non-circulating IAV strains, such as H5N1. While we have performed EMPEM on rabbit and NHP sera, herein we report the
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first study using our structure-based method to comprehensively map the polyclonal response to an avian influenza virus
vaccine in humans (Bianchi et al., 2018; Cirelli et al., 2019; Moyer
et al., 2020; Nogal et al., 2020).
Complementary serological techniques inform our understanding of the pAb response to influenza virus vaccination,
and EMPEM contextualizes data from these traditional methods.
In this study, ELISA binding titers indicated a strong stem-specific response that increased during the course of H5N1 vaccination but a low initial head-specific response that expanded after
the second immunization (Figure 1D). HAI+ antibodies were only
detected after the second immunization (Figure 1C). Ellebedy
et al. (2020) also determined that mAbs at day 7 had higher levels
of SHM and were likely generated by highly mutated memory B
cells, while mAbs at day 28 were strain-specific and were produced from naive or recently generated memory B cells.
EMPEM analyses corroborated and extended these observations by describing specific epitopes targeted on the head and
stem domains of HA, including five unique epitopes targeted
across the head domain that incorporate every known vulnerable
site on H5 HA (Figure 7A). Our analyses also elucidated atomic
level detail of the IFY motif in persistent, broadly neutralizing
stem pAbs with VH1-69 CR9114-like qualities, differentiated
overlapping antibodies and angles of approach to similar epitopes, and monitored the kinetics of each response during the
course of vaccination (Figures 3 and 4). Additionally, the number
of unique specificities in the pAb response began declining by
day 42 or 100 in two donors, supported by ELISA data also
showing declining serum IgG titers for these donors. These results demonstrate that EMPEM can track the kinetics of individual pAb specificities.
Current universal influenza vaccines focus on eliciting bnAbs
against the conserved stem of HA. However, influenza viruses
can escape from stem-targeting antibodies, although this may
be less likely for group 1 HA strains (Wu et al., 2020; Anderson
et al., 2017). Conserved regions on the head of HA, such as
the RBS, can also play an important role in universal protection
(Krammer, 2019). Therefore, eliciting bnAbs to both conserved
head and stem epitopes could strengthen universal protection
and limit the development of resistance to single epitopes. Interestingly, after the first H5N1 immunization, subject 43 elicited an
RBS-directed pAb circulating by day 21 (Figure 4). As this was
subject 43’s first exposure to novel H5 HA, it is possible that
the immunization elicited cross-reactive memory B cell responses to conserved sites on the HA head. Additionally, subject
28 still had low levels of pAbs targeting the RBS region circulating 1 year after vaccination (Figure 4). As these pAbs may
recognize conserved aspects of the RBS, they may have been
derived from a new memory B cell population that matured
and differentiated into long-lived plasma cells. In the future, we
can test this hypothesis by tracking the evolution of RBS-specific
mAbs from subject 28 during the course of the trial.
By matching binding specificities of mAbs and pAbs from corresponding serum samples, we can evaluate how well mAbs
represent the pAb response and extrapolate functional properties of pAbs. mAbs are usually isolated from plasmablasts or
memory B cells and thus may not encompass the diversity
of antibodies present in serum. In this study, mAb analyses
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demonstrated a biphasic response to H5N1 vaccination; mAbs
isolated at day 7 exclusively bound the stem domain while
mAbs from day 28 specifically bound the head domain of HA.
Interestingly, the biphasic response to HA was not fully recapitulated by EMPEM data; subject 43 also targeted the head after the
first immunization, and a large proportion of pAbs still targeted
the stem after the second immunization (Figures 3 and 4). Moreover, EM mapped day 28 mAbs bound almost exclusively to the
RBS, while day 28 EMPEM results demonstrated a diverse pAb
response to multiple head epitopes (Figures 4 and 5) (Ellebedy
et al., 2020). We used full-length H5 HA as the probe for isolating
mAbs; perhaps B cell receptor (BCRs) recognize the RBS more
readily than the stem, resulting in biased isolation of head-specific B cells. Alternatively, even though the quantity of stem
pAbs did not diminish, it is possible that the expansion of headspecific B cells at day 28 outnumbered stem-specific B cells, resulting in preferential isolation of head-specific B cells. Finally,
due to clonal expansion, mAb isolation may be biased toward
more dominant B cell clones, whereas EMPEM evaluates the total IgG pool and can identify minority epitopes. Nevertheless, we
can extract crucial details about the polyclonal response through
mAb analysis; day 7 pAbs consist of broadly reactive VH1-69 antibodies. mAb analysis provides powerful functional details of antibodies, but EMPEM is necessary to recapitulate the complexity
and dynamics of the pAb response.
Humans have lifelong exposure history with influenza viruses
and elicit immune responses mostly to the immunodominant
and drifting head of HA (Krammer, 2019). An individual’s first
influenza virus infection strongly biases their immune response
to subsequent, drifted influenza virus strains, resulting in person-to-person variation (Li et al., 2013; Andrews et al., 2015;
Gostic et al., 2016, 2019). Additionally, single Ab specificities
may functionally dominate the pAb response, rendering other
specificities inconsequential (Li et al., 2013; Huang et al., 2015;
Lee et al., 2019). This phenomenon also differs between individuals and may be influenced by pre-exposure history. Our study
establishes EMPEM as a powerful new tool for gauging pre-existing immunity and variation between individuals by mapping
bulk influenza-directed pAb responses at baseline and during
the course of vaccination to multiple antigens as well as
distinguishing differences in epitope targets per individual. Our
EMPEM results identified pre-existing, cross-reactive stem
pAbs at baseline in half of the subjects, elicitation and persistence of cross-reactive stem pAbs in all subjects after primary
exposure, and expansion of a decorated head response that varied in each subject after secondary exposure to H5 HA (Figures 3
and 4). In future studies with known patient ages and immune
histories, EMPEM will be advantageous for dissecting pAb targets between individuals, connecting pAb differences with preexposure immune profiles.
As humans are immunologically naive to avian influenza virus
strains, such as H5N1, primary exposure to their antigens may
direct the immune response to conserved epitopes predominantly located on the stem region of HA, potentially providing
broad protection against circulating and pandemic influenza virus strains (Nachbagauer and Palese, 2020). Previous studies
suggested that H5N1 vaccines are poorly immunogenic and
result in lower seroconversion rates compared to seasonal influ-

enza virus vaccination, but these conclusions are mostly based
off of HAI titers (Bresson et al., 2006; Treanor et al., 2006; Belshe
et al., 2014). In this study, we show that low-dose inactivated
H5N1 vaccination adjuvanted with AS03 elicits a potent
response to highly conserved epitopes in the stem domain
immediately after the first immunization that is sustained over a
year after vaccination. Additionally, after the second immunization we observed a head response that targets all major neutralizing sites on the head of H5 HA, potentially enhancing protection
against H5N1 strains (Figure 7A) (Zuo et al., 2015). Finally, H5N1elicited pAbs encompass broadly neutralizing sites in the stem,
esterase, and RBS of HA, emphasizing H5 HA’s utility as an antigenic candidate (Figure 7C).
Training adaptive immunity to successfully target and
neutralize multiple influenza virus strains is imperative for the
success of a universal influenza vaccine. This study underscores
the ability of novel influenza antigens to elicit memory responses
to conserved sites on HA, while also illustrating subtype-specific
responses upon re-exposure to the same strain. Therefore, immunogens in a prime/boost regimen for a universal influenza
vaccine should be from a different strain, such as a novel H7 antigen, to keep pAb responses trained on conserved epitopes in
the stem and RBS and away from off-target recalled epitopes.
Here and in future studies, EMPEM can dissect pAb responses
to influenza virus vaccinations and infections with novel and seasonal strains, enabling comparison of immune responses of humans across age groups and with varying exposure histories.
This extensive characterization of immune responses to influenza virus will contribute invaluable information for developing
universal influenza vaccines.
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KEY RESOURCES TABLE

REAGENT or RESOURCE

SOURCE

IDENTIFIER

Antibodies
10.04.7.1C01 mAb

Ellebedy laboratory (Ellebedy et al., 2020)

N/A

10.04.28.1F03 mAb

Ellebedy laboratory (Ellebedy et al., 2020)

N/A

10.04.28.1H09 mAb

Ellebedy laboratory (Ellebedy et al., 2020)

N/A

10.43.7.1A06 mAb

Ellebedy laboratory (Ellebedy et al., 2020)

N/A

10.43.7.1B02 mAb

Ellebedy laboratory (Ellebedy et al., 2020)

N/A

10.43.7.1B04 mAb

Ellebedy laboratory (Ellebedy et al., 2020)

N/A

10.43.28.1B02 mAb

Ellebedy laboratory (Ellebedy et al., 2020)

N/A

10.43.28.1A08 mAb

Ellebedy laboratory (Ellebedy et al., 2020)

N/A

10.43.28.1A02 mAb

Ellebedy laboratory (Ellebedy et al., 2020)

N/A

10.43.28.1E01 mAb

Ellebedy laboratory (Ellebedy et al., 2020)

N/A

10.43.28.1H01 mAb

Ellebedy laboratory (Ellebedy et al., 2020)

N/A

Peroxidase AffiniPure Goat Anti-Human IgG (H+L)

Jackson ImmunoResearch

Cat #109-035-088

SIGMAFAST OPD

Sigma Aldrich

Cat #P9187

Rafi Ahmed laboratory (Ellebedy et al., 2020)

N/A

Rafi Ahmed laboratory (Ellebedy et al., 2020)

NCT01910519

Bacterial and virus strains
6:2 re-assortant, low pathogenic (no multi-basic
cleavage site) H5N1 virus (A/Indonesia/05/2005
and PR8 IBCDC-RG (H5N1))
Biological samples
Serum from human subjects
Chemicals, peptides, and recombinant proteins
H5N1 monovalent, inactivated vaccine

GlaxoSmithKline

N/A

AS03

GlaxoSmithKline

N/A

HA from A/Indonesia/5/2005 (H5N1)

International Reagent Resource

FR-59

Trimeric head domain of HA from A/Indonesia/5/2005

Rafi Ahmed laboratory (Ellebedy et al., 2014)

N/A

Chimeric HA: stem from A/Indonesia/5/2005, head
from A/guinea fowl/Hong Kong/WF10/1999 (H9N2)

Rafi Ahmed laboratory (Ellebedy et al., 2014)

N/A

HA from A/California/04/2009 (H1N1)

Produced in house

N/A

HA from A/Michigan/45/2015 (H1N1)

Ian Wilson laboratory

N/A

HA from A/Singapore/1/1957 (H2N2)

Adrian McDermott laboratory

N/A

HA from A/Singapore/INFIMH-16-0019/2016 (H3N2)

James Crowe laboratory

N/A

Protein G Resin 4 FastFlow

GE Healthcare

Cat #17-0618-05

CaptureSelect IgG-Fc (ms) Affinity Matrix

Thermo Fisher

Cat #1912855250

Immobilized papain

Thermo Fisher

Cat #20341

Papain from papaya latex

Sigma Aldrich

Cat #P3125

Superose 6 increase 10/300 size exclusion column

GE Healthcare

Cat #17-5172-01

Superdex 200 increase 10/300 size exclusion column

GE Healthcare

Cat #17-5175-01

CaptureSelect CH1-XL column

Thermo Fisher

Cat #494346201

Uranyl Formate

Electron Microscopy Sciences

Cat #D310 25 GM

Lauryl Maltose Neopentyl Glycol

Anatrace

Cat #NG310 5 GM

Zeba Spin Desalting Columns, 7K MWCO

Thermo Fisher

Cat #89883

20X HBS-EP buffer

Teknova

Cat #H8022

Bovine Serum Albumins

Sigma Aldrich

Cat #A7906
(Continued on next page)
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EZ-Link-NHS-PEG4-Biotin

Thermo Fisher

Cat # 21363

Streptavidin (SA) Biosensors

ForteBio

Cat #18-5019

CM5 sensor chips

GE Healthcare

Cat #29149604

Polyclonal immune complex of Fab binding the stem
of H5 HA from serum of subject 4 at day 21

EMDataBank

EMD-22536

Polyclonal immune complex of Fab binding the stem
of H5 HA from serum of subject 4 at day 28

EMDataBank

EMD-22537

Polyclonal immune complex of Fab binding the side
of the head of H5 HA from serum of subject 4 at day 28

EMDataBank

EMD-22538

Polyclonal immune complex of Fab binding the side
of the head of H5 HA from serum of subject 4 at day 28

EMDataBank

EMD-22539

Polyclonal immune complex of Fab binding the
receptor binding site region of H5 HA from serum
of subject 4 at day 28

EMDataBank

EMD-22540

Polyclonal immune complex of Fab binding the top
of the head of H5 HA from serum of subject 4 at day 28

EMDataBank

EMD-22541

Polyclonal immune complex of Fab binding the stem
of H5 HA from serum of subject 4 at day 42

EMDataBank

EMD-22542

Polyclonal immune complex of Fab binding the stem
of H5 HA from serum of subject 28 at day 7

EMDataBank

EMD-22543

Polyclonal immune complex of Fab binding the stem
of H5 HA from serum of subject 28 at day 21

EMDataBank

EMD-22544

Polyclonal immune complex of Fab binding the stem
of H5 HA from serum of subject 28 at day 28

EMDataBank

EMD-22545

Polyclonal immune complex of Fab binding the
receptor binding site region of H5 HA from serum
of subject 28 at day 28

EMDataBank

EMD-22546

Polyclonal immune complex of Fab binding the top
of the head of H5 HA from serum of subject 28 at day 28

EMDataBank

EMD-22547

Polyclonal immune complex of Fab binding the stem
of H5 HA from serum of subject 36 at day 0

EMDataBank

EMD-22548

Polyclonal immune complex of Fab binding the stem
of H5 HA from serum of subject 36 at day 7

EMDataBank

EMD-22549

Polyclonal immune complex of Fab binding the stem
of H5 HA from serum of subject 36 at day 21

EMDataBank

EMD-22550

Polyclonal immune complex of Fab binding the
receptor binding site region of H5 HA from serum
of subject 36 at day 28

EMDataBank

EMD-22551

Polyclonal immune complex of Fab binding the stem
of H5 HA from serum of subject 36 at day 500

EMDataBank

EMD-22552

Polyclonal immune complex of Fab binding the stem
of H5 HA from serum of subject 43 at day 7

EMDataBank

EMD-22553

Polyclonal immune complex of Fab binding the stem
of H5 HA from serum of subject 43 at day 7

EMDataBank

EMD-22554

Polyclonal immune complex of Fab binding the stem
of H5 HA from serum of subject 43 at day 21

EMDataBank

EMD-22555

Polyclonal immune complex of Fab binding the stem
of H5 HA from serum of subject 43 at day 28

EMDataBank

EMD-22556

Polyclonal immune complex of Fab binding the stem
of H5 HA from serum of subject 43 at day 28

EMDataBank

EMD-22557

Critical commercial assays

Deposited data

(Continued on next page)
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Polyclonal immune complex of Fab binding the
receptor binding site region of H5 HA from serum
of subject 43 at day 28

EMDataBank

EMD-22558

Polyclonal immune complex of Fab binding the stem
of H5 HA from serum of subject 43 at day 100

EMDataBank

EMD-22559

Polyclonal immune complex of Fab binding the
receptor binding site region of H5 HA from serum
of subject 43 at day 100

EMDataBank

EMD-22560

Monoclonal immune complex of Fab 1A06 from
participant 43 at day 7 binding the stem of H5 HA

EMDataBank

EMD-22561

Monoclonal immune complex of Fab 1B02 from
participant 43 at day 7 binding the stem of H5 HA

EMDataBank

EMD-22562

Monoclonal immune complex of Fab 1B04 from
participant 43 at day 7 binding the stem of H5 HA

EMDataBank

EMD-22563

Monoclonal immune complex of Fab 1A02 from
participant 43 at day 28 binding the stem of H5 HA

EMDataBank

EMD-22564

Monoclonal immune complex of Fab 1A08 from
participant 43 at day 28 binding the stem of H5 HA

EMDataBank

EMD-22565

Monoclonal immune complex of Fab 1H01 from
participant 43 at day 28 binding the stem of H5 HA

EMDataBank

EMD-22566

Monoclonal immune complex of Fab 1E01 from
participant 43 at day 28 binding the stem of H5 HA

EMDataBank

EMD-22567

Polyclonal immune complex of Fab binding the stem
of H1 HA from serum of subject 43 at day 21

EMDataBank

EMD-22568

CryoEM polyclonal immune complex of Fab binding
the stem of H5 HA from serum of subject 4 at day 28

EMDataBank

EMD-22569

CryoEM polyclonal immune complex of Fab binding
the stem of H5 HA from serum of subject 4 at day 28

EMDataBank

EMD-22570

CryoEM polyclonal immune complex of Fab binding
the stem of H5 HA from serum of subject 4 at day 28

EMDataBank

EMD-22571

CryoEM polyclonal immune complex of Fab binding
the stem of H5 HA from serum of subject 4 at day 28

EMDataBank

EMD-22572

Chicken red blood cells

Lampire

Cat #7241408

Freestyle 293-F cells

Thermo Fisher

Cat# R79007

Unicorn 7.0

GE Healthcare

https://www.cytivalifesciences.com/

Leginon

Suloway et al. (2005)

N/A

Appion

Lander et al. (2009)

N/A

DoG Picker

Voss et al. (2009)

N/A

Relion

Scheres (2012)

N/A

Cryosparc2

Punjani et al. (2017)

N/A

UCSF Chimera

Pettersen et al. (2004)

N/A

Negative stain EM grids, 400 mesh

Electron Microscopy Sciences

Cat #EMS400-CU

CryoEM grids, quantifoil 1.2/1.3, 00 mesh

Electron Microscopy Sciences

Q4100CR1.3-2nm

Experimental models: cell lines

Software and algorithms

Other

RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Andrew B.
Ward (andrew@scripps.edu).
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Materials availability
This study did not generate new unique reagents.
Data and code availability
3D EM reconstructions have been deposited to The Electron Microscopy Data Bank (emdataresource.org). The accession numbers,
also listed in the Key Resources Table, are EMDataBank: EMD-22536, EMD-22537, EMD-22538, EMD-22539, EMD-22540, EMD22541, EMD-22542, EMD-22543, EMD-22544, EMD-22545, EMD-22546, EMD-22547, EMD-22548, EMD-22549, EMD-22550,
EMD-22551, EMD-22552, EMD-22553, EMD-22554, EMD-22555, EMD-22556, EMD-22557, EMD-22558, EMD-22559, EMD22560, EMD-22561, EMD-22562, EMD-22563, EMD-22564, EMD-22565, EMD-22566, EMD-22567, EMD-22568, EMD-22569,
EMD-22570, EMD-22571, EMD-22572.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
The vaccination trial (ClinicalTrials.gov: NCT01910519) has been described previously and was approved by the Institutional
Review Board of Emory University (Ellebedy et al., 2020). Briefly, healthy adult male and female participants between 21-45 years
old were immunized with monovalent inactivated A/Indonesia/05/2005 (H5N1) influenza vaccine with AS03 adjuvant provided by
GlaxoSmithKline. All participants provided informed consent. Plasma and peripheral blood mononuclear cells (PBMCs) were
collected at days 0, 7, 21, 28, 42, 100, and 500 after the first immunization.
METHOD DETAILS
ELISA
We coated 96-well plates with recombinant HA (A/Indonesia/5/2005) overnight at 4 C. Following HA binding, we incubated the plates
at room temperature for 1 hour with blocking buffer (0.1% Tween 20, 0.5% milk powder, 3% goat serum in phosphate-buffered saline
(PBS)). Next, we incubated serial dilutions of mAbs on HA-coated plates at room temperature for 2 hours followed by three washes
with 0.1% Tween 20 in PBS. We added secondary goat anti-human IgG conjugated to horse radish peroxidase at 1:3000 dilution in
blocking buffer to plates and incubated at room temperature for 1 hour. Finally, we washed the plates four times with 0.1% Tween 20
in PBS, added SigmaFast o-phenylenediamine solution, and measured 490nm signal using a plate reader. To distinguish head and
stem responses, we used the trimeric head domain from A/Indonesia/5/2005 and chimeric HA expressing the stem from A/Indonesia/
5/2005 and the head of H9 from A/guinea fowl/Hong Kong/WF10/1999 (H9N2), produced recombinantly using the baculovirus
expression system described previously (Ellebedy et al., 2014).
HA inhibition
We added serially diluted mAbs at an initial concentration of 30 mg/mL in PBS to V-shaped 96-well plates in duplicate. Next, we added
8 HA units/50 mL of 6:2 re-assortant, low pathogenic (no multi-basic cleavage site) H5N1 virus (A/Indonesia/05/2005 and PR8 IBCDCRG (H5N1)) to each well and incubated plates at room temperature for 30 min with shaking. We added 0.5% chicken red blood cells to
each well and incubated plates at 4 C until red blood cells formed puncta at the bottom of the negative control wells. We measured
minimum HAI concentration by determining the last dilution well that did not display hemagglutination.
mAb production
Antibodies were cloned as previously described (Wrammert et al., 2008). Total or H5 HA probe-binding plasmablasts were single cell
sorted into 96-well plates containing RNA stabilizing buffer. VH, Vk, and Vl genes were then amplified by reverse transcription-PCR
and nested PCR reactions from singly-sorted GC B cells and PBs using cocktails of primers specific for IgG, IgM/A, Igk, and Igl from
previously detailed primer sets and then sequenced. The amplified VH, Vk, and Vl genes were cloned into IgG1 and Igk expression
vectors, respectively, as previously described. Heavy and light chain plasmids were co-transfected into Expi293F cells (GIBCO) for
expression and antibody was purified with protein A agarose (Invitrogen).
Antibody affinity measurements
To measure binding affinities and off-rates of HA to Fabs, we first digested mAbs to Fab with immobilized papain (Thermo Fisher) and
purified the digestion products over a protein A/G affinity column to isolate Fab. We biotinylated HA in vitro (EZ-Link-NHS-PEG4Biotin, Thermo Fisher) and removed excess biotin with a desalting column (0.5mL Zeba Spin 7K MWCO, Thermo Fisher). We
measured binding parameters of each Fab to HA by bio-layer interferometry (BLI) using an Octet Red96 instrument (ForteBio) or surface plasmon resonance (SPR) using a Biacore T200 SPR instrument (GE Healthcare). Using BLI, we performed a preliminary experiment to identify Fabs with too low signal-to-noise ratio to quantify; for higher sensitivity, we conducted SPR analyses for these Fabs.
For BLI, we loaded 5 mg/mL biotinylated HA in HBS-EP buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.005% P20
surfactant) with 1% BSA onto streptavidin biosensors (ForteBio) for 1min. For SPR, we coupled neutravidin protein to CM5
sensor chips using standard amine-coupling and then captured biotinylated HA in HBS-EP buffer, which resulted in a response of
200-300 RU. We measured Fabs in 3-fold serial dilutions at 25 C and processed data using Biaevaluation 3.1 (GE Healthcare).
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We employed a 1:1 binding model to measure association and dissociation rate constants and fit steady-state equilibrium concentration curves.
Serum IgG purification, digestion, and complexing
To purify IgG from serum samples we heat inactivated 1 mL serum samples in a 55 C water bath for 30 min and incubated them on
protein G resin (GE Healthcare) or Capture Select (Thermo Fisher) in a 1:1 ratio of serum to resin for 20 hours to bind IgG. After incubation, we removed IgG-depleted serum and washed IgG-bound protein G samples three times with PBS using centrifugation and
Amicon concentrators. Next, to elute IgG from protein G resin, we incubated the samples in 0.1M glycine pH 2.5 buffer for 20 min
followed by neutralization with 1M Tris-HCl pH 8 buffer, repeated twice. We buffer exchanged the samples into PBS using centrifugation with Amicon concentrators. For IgG digestion, we incubated 4 mg IgG with immobilized papain (Thermo Fisher) in freshly-prepared digestion buffer (20mM sodium phosphate, 10 mM EDTA, 20 mM cysteine, pH 7.4) at 37 C for 18-22 hours. We separated
digested IgG and immobilized papain using Pierce spin columns (Thermo Fisher) and buffer exchanged digested IgG into tris-buffered saline (TBS) using centrifugation with Amicon concentrators. To separate Fab/Fc from IgG we ran the samples through size
exclusion chromatography with a Superdex 200 increase 10/300 column (GE Healthcare). For complexing, we concentrated 1mg
Fab/Fc to 50 mL and incubated with 20 mg recombinant HA at room temperature for 16-20 hours. Finally, we purified immune complexes from unbound Fab/Fc through size exclusion chromatography with a Superose 6 increase 10/300 column (GE Healthcare) and
concentrated the immune complexes to 50 mL.
mAb digestion and complexing for EM
To digest monoclonal IgG to Fab, we first incubated papain in freshly-prepared digestion buffer (100mM Tris pH 8, 2mM EDTA, 10mM
L-cysteine) at 37 C for 15min. Next, we incubated activated papain with 1mg IgG in freshly-prepared digestion buffer at 37 C for
2 hours. To end the digestion, we added 50mM iodoacetamide. We buffer exchanged the digestion products into PBS using centrifugation with Amicon concentrators and purified Fabs using a CaptureSelect CH1-XL column (Thermo Fisher), eluting Fab with
150 mM sodium chloride and 20mM sodium acetate pH 3.4 buffer and neutralizing with 1M Tris-HCl pH 8 buffer. We buffer
exchanged and concentrated Fab into PBS using centrifugation with Amicon concentrators and complexed Fab with HA at greater
than 3x molar ratio of Fab to HA at 4 C for 16-20 hours.
Negative stain electron microscopy
To prepare grids for negative stain electron microscopy, we deposited purified immune complexes at 30 mg/mL onto glow-discharged, carbon-coated 400 mesh copper grids (Electron Microscopy Sciences, EMS). After blotting to remove excess sample,
we stained the grids with 2% w/v uranyl formate for 30 s followed by blotting to remove excess stain. We imaged the grids on a Talos
200C with a Falcon II direct electron detector and a CETA 4k camera (FEI) at 200kV, 73,000x magnification, and 1.98Å/pixel, a Tecnai
Spirit T12 (FEI) with a CMOS 4k camera (TVIPS) at 120kV, 52,000x magnification, and 2.06Å/pixel, and a Tecnai T20 (FEI) with an
Eagle CCD 4k camera (FEI) at 200kV, 62,000x magnification, and 1.77Å/pixel. We collected micrographs using Leginon, picked
and stacked 100,000-400,000 single particles using Appion, and processed particles to reference-free 2D class averages and 3D
reconstructions using Relion (Suloway et al., 2005; Lander et al., 2009; Scheres, 2012; Zivanov et al., 2018). We used UCSF Chimera
to analyze data and generate figures (Pettersen et al., 2004). Due to low angular sampling induced by particle orientation bias and low
abundance of immune complexes, a small proportion of immune complexes only partially reconstructed in 3D but clearly showed
Fab placement relative to HA. These placements were also confirmed by distinct 2D class averages. Similarly to Gilchuk et al.
(2019), we used our internal database of HA immune complexes, partial 3D density, and distinguishing 2D class averages as references to project these specificities onto 3D models of HA and mark them as predicted placements.
CryoEM
To freeze grids for cryoEM, we added Lauryl Maltose Neopentyl Glycol (Anatrace) at a final concentration of 5 mM to purified immune
complexes at 750 mg/mL and deposited samples immediately onto glow-discharged 1.2/1.3 quantifoil 400 grids (EMS). After incubating samples on grids for 7 s, we blotted off excess sample and froze grids in liquid ethane using a Vitrobot (FEI). We transferred
grids to liquid nitrogen for storage. We imaged cryoEM grids on a Titan Krios (FEI) with a Gatan K2 summit detector operating at
300kV. We collected 2,559 micrographs in counting mode at 29,000 nominal magnification, 1.03Å/pixel, using Leginon (Suloway
et al., 2005). Our total exposure time was 10.5 s with a total dose of 53.1 electrons/Å2. After performing motion-correction and
GCTF estimation, we picked particles using a difference-of-Gaussians picker (Voss et al., 2009; Zhang, 2016; Zheng et al., 2017).
We performed initial reference-free 2D classification in Cryosparc followed by further 2D classification in Relion (Punjani et al.,
2017; Zivanov et al., 2018). Next, we ran global 3D refinement with 3-fold symmetry expansion on the total particles after 2D cleanup.
As pAb:HA complexes represented a minority of the total particles—mostly unbound HA and Fab—and were difficult to identify in 2D
class averages, we turned to focus classification to guide identification, isolation, and refinement of each immune complex. In Relion,
using the corresponding negative stain epitope landscape for subject 4 at day 28 as a guide, we positioned 40A sphere masks over
expected pAbs and ran 3D classification without image alignment or imposed symmetry for each specificity. After identifying and
classifying each unique pAb complex, we refined and post-processed each specificity with a mask around the entire immune complex. For our 4.7 Å resolution map of the stem-specific immune complex, we generated a predicted model of mAb 1C01 from subject
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4 at day 7 using ROSIE (The Rosetta Online Server that Includes Everyone) and used Coot to minimally adjust the flexible CDR H3 loop
into density (Emsley and Cowtan, 2004; Lyskov et al., 2013; Weitzner et al., 2017). As our resolution was not high enough, we did not
further refine a model of 1C01 into the stem immune complex map.
QUANTIFICATION AND STATISTICAL ANALYSIS
We conducted statistical analyses in GraphPad Prism.
ADDITIONAL RESOURCES
More information about this clinical trial is located at clinicaltrials.gov under the identifier NCT01910519.
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Supplemental Figure 1. Related to Figure 1. Affinity assessment of mAbs from subjects 4,
28, 36, and 43.
(A) ELISA binding titers of serum IgG to recombinant H5 HA over the course of vaccination.
(B-C) affinity measurements (B) and off-rates (C) of H5 HA stem- (blue) and head-specific (red)
plasmablast-derived monoclonal Fab fragments isolated at days 7 and 28 binding to recombinant
H5 HA. (D-E) Representative biolayer interferometry (BLI) binding curves of monoclonal Fab
fragments 1A06 (D) and 1H01 (E) isolated from subject 43 at days 7 and 28 binding to
recombinant H5 HA. p-values were determined by unpaired t tests: * p-value <0.05, ** p-value <
0.01, *** p-value < 0.001, **** p-value < 0.0001, N.S. non-significant.

Supplemental Figure 2. Related to Figure 2. Purification of polyclonal immune complexes.
(A) Example chromatogram from size exclusion chromatography separation of polyclonal immune
complexes. Peaks corresponding to elution of immune complexes and excess Fab are labeled.

Supplemental Figure 3. Related to Figure 3. Subject 4 2D class averages over the course
of H5N1 vaccination.
(A) Example 2D class averages of immune complexes or unbound H5 HA at corresponding time
points after H5N1 vaccination in subject 4.

Supplemental Figure 4. Related to Figure 4. Subjects 28, 36, and 43 2D class averages over
the course of H5N1 vaccination.
(A) Example 2D class averages of immune complexes or unbound H5 HA at corresponding time
points after H5N1 vaccination in subjects 28, 36, and 43.

Supplemental Figure 5. Related to Figure 5. Subject 43 mAbs target discrete regions on
HA.
(A) Table of mAbs isolated from plasmablasts of subjects 4 and 43. Variable gene usages and
EM-mapped epitopes are listed. (B-C) 3D reconstructions of immune complexes from day 7 (B)
or day 28 (C) plasmablasts with recombinant H5 HA (A/Indonesia/5/2005).

Supplemental Figure 6. Related to Figure 6. CryoEM maps of polyclonal immune
complexes.
(A) Workflow of cryoEM focused classification and refinement: Briefly, after cryoEM data
collection and initial processing steps, particles are classified and cleaned in 2D. All particles are
masked around the HA trimer, aligned to a reference HA trimer (PDB 4K62), and C3 symmetry
expanded. For focused classification, particles are classified in 3D without global image alignment
using a 40 Å spherical mask around regions of anticipated pAbs. For focused refinement, 3D
classes of individual immune complexes are further refined with a mask around the immune
complex. Final maps of specific immune complexes are then produced from multiple iterations of
focused classification and refinement. Scale bar on micrograph denotes 100nm. (B-E) CryoEM
maps of pAbs in complex with recombinant H5 HA (A/Indonesia/5/2005). Maps were low-pass
filtered to 9A for the RBS-specific (B), 8A for the lateral patch-specific (C), 10A for the vestigial
esterase-specific (D), and 6A for the stem-specific (E) immune complexes. (F) CryoEM map of

stem-specific immune complex in gray and green with CR9114 ribbon diagram docked into EM
density (PDB 4FQI). (G) CryoEM map of stem-specific immune complex in grey compared with
subject 4 day 7 mAb 1C01 complexed with H5 HA in blue.

Supplemental Figure 7. Related to Figure 7. Subject 43 2D class averages of immune
complexes with heterosubtypic H1 HA.
(A) Example 2D class averages of H1 HA (A/Michigan/45/2015) immune complexes at day 21 in
subject 43.

